Alzheimer’s trials increasingly sponsored by public sector: Data Byte

The public sector is picking up the slack after many biopharma companies exited Alzheimer’s drug development, according to a new study published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.

The analysis, conducted by Garam Lee of  Biogen Inc. (NASDAQ:BIIB) and Jeffrey Cummings and Justin Bauzon of the University of Nevada Las Vegas, surveyed the sponsors of clinical trials with U.S. sites listed on ClinicalTrials.gov and found that since 2016, the number of trials funded by biopharmas has declined while the number of trials sponsored by NIH, academic centers, or public-private partnerships has increased...